Literature DB >> 6738342

Cavitary histoplasmosis occurring during two large urban outbreaks. Analysis of clinical, epidemiologic, roentgenographic, and laboratory features.

L J Wheat, J Wass, J Norton, R B Kohler, M L French.   

Abstract

We have compared risk factors for cavitary histoplasmosis in 62 patients with that manifestation of the infection and in 679 patients with other forms of histoplasmosis, and we have evaluated the clinical and laboratory findings in 45 patients with cavitary histoplasmosis who were cared for at the Indiana University Medical Center hospitals during two large histoplasmosis outbreaks. Chronic obstructive lung disease and old age were the strongest risk factors for cavitary histoplasmosis but male sex, white race and immunosuppression were also important in certain patient groups. Fever, sweats, weight loss, productive cough, anemia, lymphopenia, and alkaline phosphatase elevation were common findings. The patients were occasionally incorrectly treated for presumed class 3 tuberculosis. Cultures were positive in 58% of patients, with sputum samples providing the highest yield (61%). Histoplasmal serologic tests provided useful clues to the diagnosis, positive in over 90% of cases. About one-third of patients recovered spontaneously while another 35% improved following treatment. About 4% developed chronic untreated cavitary histoplasmosis characterized by clinical and roentgenographic exacerbations and remissions. Of the deaths in four patients with untreated disease, one was caused by disseminated histoplasmosis while three died of other causes. Ketoconazole appeared effective in three of seven patients while its effect in three additional patients was uncertain. Toxicity precluded completion of ketoconazole therapy in one patient. Only amphotericin B has been proven to be effective therapy for cavitary histoplasmosis.

Entities:  

Mesh:

Year:  1984        PMID: 6738342     DOI: 10.1097/00005792-198407000-00002

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  14 in total

Review 1.  Histoplasmosis: a clinical and laboratory update.

Authors:  Carol A Kauffman
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 3.  Tropical respiratory medicine. 3. Histoplasmosis and pulmonary involvement in the tropics.

Authors:  S Houston
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

Review 4.  Diagnosis and management of histoplasmosis.

Authors:  L J Wheat
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

5.  Pulmonary Histoplasmosis.

Authors:  Carol A. Kauffman
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

6.  Enhanced Surveillance for Histoplasmosis-9 States, 2018-2019.

Authors:  Kaitlin Benedict; Stephanie McCracken; Kimberly Signs; Malia Ireland; Victoria Amburgey; Jose Antonio Serrano; Natalie Christophe; Suzanne Gibbons-Burgener; Sara Hallyburton; Kimberly A Warren; Alison Keyser Metobo; Racheal Odom; Matthew R Groenewold; Brendan R Jackson
Journal:  Open Forum Infect Dis       Date:  2020-08-17       Impact factor: 3.835

Review 7.  Fungal infections: a growing threat.

Authors:  D M Dixon; M M McNeil; M L Cohen; B G Gellin; J R La Montagne
Journal:  Public Health Rep       Date:  1996 May-Jun       Impact factor: 2.792

8.  Validation and clinical application of a molecular method for identification of Histoplasma capsulatum in human specimens in Colombia, South America.

Authors:  Cesar Muñoz; Beatriz L Gómez; Angela Tobón; Karen Arango; Angela Restrepo; Margarita M Correa; Carlos Muskus; Luz Elena Cano; Angel González
Journal:  Clin Vaccine Immunol       Date:  2009-11-25

Review 9.  Histoplasma Capsulatum: Mechanisms for Pathogenesis.

Authors:  Jamie Mittal; Maria G Ponce; Inessa Gendlina; Joshua D Nosanchuk
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

10.  Chronic pulmonary histoplasmosis in the State of Rio de Janeiro, Brazil.

Authors:  D Capone; B Wanke; P C Monteiro; M S Lazéra; G de Noronha Andrade; A C do Valle; A M Moreno; A T Londero
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.